Ultragenyx Pharmaceutical Inc. Quarterly Additional Paid in Capital in USD from Q1 2014 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
Ultragenyx Pharmaceutical Inc. quarterly Additional Paid in Capital history and growth rate from Q1 2014 to Q3 2024.
  • Ultragenyx Pharmaceutical Inc. Additional Paid in Capital for the quarter ending September 30, 2024 was $4.17B, a 26.4% increase year-over-year.
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $4.17B +$871M +26.4% Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $4.12B +$886M +27.4% Jun 30, 2024 10-Q 2024-08-02
Q1 2024 $3.7B +$530M +16.7% Mar 31, 2024 10-Q 2024-05-03
Q4 2023 $3.66B +$522M +16.6% Dec 31, 2023 10-Q 2024-11-06
Q3 2023 $3.3B +$190M +6.12% Sep 30, 2023 10-Q 2023-11-03
Q2 2023 $3.24B +$166M +5.4% Jun 30, 2023 10-Q 2023-08-04
Q1 2023 $3.17B +$141M +4.64% Mar 31, 2023 10-Q 2023-05-05
Q4 2022 $3.14B +$143M +4.76% Dec 31, 2022 10-K 2024-02-21
Q3 2022 $3.11B +$223M +7.75% Sep 30, 2022 10-Q 2022-11-03
Q2 2022 $3.07B +$221M +7.75% Jun 30, 2022 10-Q 2022-07-29
Q1 2022 $3.03B +$219M +7.78% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 $3B +$224M +8.09% Dec 31, 2021 10-K 2023-02-17
Q3 2021 $2.88B +$624M +27.6% Sep 30, 2021 10-Q 2021-11-03
Q2 2021 $2.85B +$629M +28.3% Jun 30, 2021 10-Q 2021-08-03
Q1 2021 $2.81B +$648M +29.9% Mar 31, 2021 10-Q 2021-05-05
Q4 2020 $2.77B +$686M +32.9% Dec 31, 2020 10-K 2022-02-15
Q3 2020 $2.26B +$194M +9.4% Sep 30, 2020 10-Q 2020-10-27
Q2 2020 $2.22B +$175M +8.57% Jun 30, 2020 10-Q 2020-07-31
Q1 2020 $2.16B +$149M +7.39% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 $2.09B +$447M +27.3% Dec 31, 2019 10-K 2021-02-12
Q3 2019 $2.07B +$461M +28.7% Sep 30, 2019 10-Q 2019-11-06
Q2 2019 $2.05B +$486M +31.2% Jun 30, 2019 10-Q 2019-08-02
Q1 2019 $2.01B +$487M +31.9% Mar 31, 2019 10-Q 2019-05-07
Q4 2018 $1.64B +$418M +34.2% Dec 31, 2018 10-K 2020-02-14
Q3 2018 $1.61B +$482M +42.8% Sep 30, 2018 10-Q 2018-11-06
Q2 2018 $1.56B +$454M +41.1% Jun 30, 2018 10-Q 2018-08-03
Q1 2018 $1.53B +$440M +40.5% Mar 31, 2018 10-Q 2018-05-08
Q4 2017 $1.22B +$218M +21.7% Dec 31, 2017 10-K 2019-02-20
Q3 2017 $1.12B +$209M +22.8% Sep 30, 2017 10-Q 2017-11-03
Q2 2017 $1.11B +$267M +31.9% Jun 30, 2017 10-Q 2017-07-28
Q1 2017 $1.09B +$260M +31.4% Mar 31, 2017 10-Q 2017-05-05
Q4 2016 $1B +$187M +22.9% Dec 31, 2016 10-K 2018-02-21
Q3 2016 $915M +$109M +13.5% Sep 30, 2016 10-Q 2016-11-08
Q2 2016 $838M +$328M +64.4% Jun 30, 2016 10-Q 2016-08-09
Q1 2016 $827M +$326M +64.9% Mar 31, 2016 10-Q 2016-05-10
Q4 2015 $817M +$492M +152% Dec 31, 2015 10-K 2017-02-17
Q3 2015 $806M +$484M +151% Sep 30, 2015 10-Q 2015-11-10
Q2 2015 $510M +$250M +96.4% Jun 30, 2015 10-Q 2015-08-14
Q1 2015 $502M +$243M +94% Mar 31, 2015 10-Q 2015-05-12
Q4 2014 $324M Dec 31, 2014 10-K 2016-02-26
Q3 2014 $322M Sep 30, 2014 10-Q 2014-11-10
Q2 2014 $260M Jun 30, 2014 10-Q 2014-08-11
Q1 2014 $259M Mar 31, 2014 10-Q 2014-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.